#### Review

# Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Adults With Psychiatric Disorders: Systematic and Meta-Analytic Review

Kazuki Matsumoto<sup>1,2</sup>, PhD; Sayo Hamatani<sup>1,3,4</sup>, PhD; Eiji Shimizu<sup>1,5,6</sup>, MD, PhD

## **Corresponding Author:**

Kazuki Matsumoto, PhD Research Center for Child Mental Development Chiba University 1-8-1, Inohana, Chuo-ku, Chiba Japan

Phone: 81 43 226 2975 Fax: 81 43 226 8588

Email: axpa0219@chiba-u.jp

## **Abstract**

**Background:** Cognitive behavioral therapy (CBT) is the gold standard of psychotherapy for psychiatric disorders. However, the format of delivering CBT in person limits access to the intervention. The advancements in information and communication technology, especially the internet, present an opportunity for cognitive behavioral therapists to service patients or clients in remote areas through videoconferencing. Although many randomized controlled trials of videoconference-delivered cognitive behavioral therapy (VCBT) have already been conducted, the overall estimated effect size of VCBT for psychiatric disorders has not been examined by systematic reviews and meta-analyses.

**Objective:** This study attempts to evaluate the effectiveness of VCBT for psychiatric disorders through a systematic and meta-analytic review.

**Methods:** A systematic review and meta-analysis of studies in which VCBT was directly compared to control groups (such as treatment as usual, attention control, wait-list control, and other minimal supports) was carried out. To identify previous studies that meet our study objective, 2 independent reviewers undertook a systematic search through seven databases: MEDLINE (via PubMed), Web of Science, Science Direct, PsycINFO, CINAHL, LILACS, and SciELO. Other databases (ClinicalTrials.gov and Cochrane Central Resister of Controlled Trials) were also checked. All studies included in the review were assessed using the quality criteria of the Cochrane Collaboration. Statistical analysis was performed by using Cochrane Review Manager (RevMan, version 5.4.0). Standardized mean difference was used in major meta-analyses where a *P* value of .05 or less was the threshold for statistical significance. A heterogeneity test and the chi-square test were performed to assess the presence and extent of statistical heterogeneity with significance set at *P*<.10. Funnel plots were visually inspected to assess the risk of bias. Subgroup analyses were conducted for each disorder to estimate intervention effects.

**Results:** The systematic search resulted in 16 studies (total N=1745) that met the criteria for this study and were included in the review. There were 10 studies on depressive symptoms, 3 on chronic pain, 1 on generalized anxiety disorder, 1 on obsessive-compulsive disorder, and 1 on hypochondriasis. The quality and risk of bias was also assessed. Results showed a pooled effect size (Hedge g) post treatment of -0.49 (95% CI -0.68 to -0.29), indicating that VCBT is effective for clients with psychiatric disorders. Study quality did not affect outcomes.



Research Center for Child Mental Development, Chiba University, Chiba, Japan

<sup>&</sup>lt;sup>2</sup>Laboratory of Neuropsychology, Institute of Liberal Arts and Science, Kanazawa University, Kanazawa, Japan

<sup>&</sup>lt;sup>3</sup>Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden

<sup>&</sup>lt;sup>4</sup>Research Center for Child Mental Development, University of Fukui, Fukui, Japan

<sup>&</sup>lt;sup>5</sup>Department of Cognitive Behavioral Physiology, Graduate School of Medicine, Chiba University, Chiba, Japan

<sup>&</sup>lt;sup>6</sup>Cognitive Behavioral Therapy Center, Chiba University Hospital, Chiba, Japan

**Conclusions:** While the overall results indicate the effectiveness of VCBT, there are still only a limited number of studies on specific psychiatric and somatic conditions. Therefore, more randomized controlled trials are needed to establish the effectiveness of VCBT for different disorders.

**Trial Registration:** International Prospective Register of Systematic Reviews (PROSPERO) CRD42021224832; https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID=224832

(J Med Internet Res 2021;23(12):e31293) doi: 10.2196/31293

#### **KEYWORDS**

videoconference-delivered cognitive behavioral therapy; depression; anxiety; psychiatric disorders; systematic review; meta-analysis; digital health; mental health; cognitive therapy; internet-based therapy; cognition; neurodevelopment; communication technology; health technology; psychological disorders; anxiety disorder


# Introduction

# **Background**

The incidence of mental health disorders has significant socioeconomic implications for public health and human rights globally. Depression, for example, is a leading cause of disability, affecting an estimated 264 million people worldwide [1]. It has been shown that cognitive behavioral therapy (CBT) is an effective treatment for a variety of mental disorders [2,3]. Cognitive behavioral therapists analyze the effects of their patients' cognition and behavior on psychiatric symptoms [4,5], and work toward developing adaptive cognitive-behavioral techniques with their client [6,7]. Evidence suggests that CBT is effective not only for psychiatric disorders [8] but also for somatic disorders [9]. It is considered the gold standard in the treatment of mental health disorders because it is substantiated by theory and research [10]. Further, evidence suggests that CBT is superior to other modalities, such as interpersonal psychotherapy [11]. The World Health Organization (2019) has also recognized its effectiveness and stated that access to CBT is important [12]. Face-to-face therapy is the most common format for providing treatment for mental health issues. However, this can restrict access to CBT for patients living in remote areas. Considering the widespread use of the internet and telecommunications equipment [13], there is a window of opportunity to provide access to CBT to patients living in remote areas [14]. Most remote CBT is delivered with the help of websites/webpages, under the guidance of a therapist. This format is called internet-based cognitive behavioral therapy (ICBT) or simply "internet intervention." According to Olthuis et al [15], "to be considered an Internet intervention, CBT must have been delivered over the Internet through the use of web pages or e-mail, or both." Two systematic reviews including meta-analyses have suggested that in terms of effectiveness, ICBT is equivalent to face-to-face CBT [16,17].

#### **Videoconference-Delivered CBT**

Another approach to improve accessibility to CBT for individuals residing in remote areas is to utilize a videoconferencing system [18-20]. In comparison to ICBT, videoconference-delivered CBT (VCBT) has the advantage of enabling remote treatment through interactive real-time communication between the therapist and the patient, which makes it similar to face-to-face CBT. At the same time, VCBT differs from face-to-face CBT because there is a "physical



Despite these concerns, results from previous clinical trials investigating the feasibility and efficacy of VCBT were generally promising [18-21]. The results from prospective and rigorous clinical trials (RCTs) have suggested that VCBT is not inferior to face-to-face CBT for the treatment of depression and posttraumatic stress disorder [22-25]. An existing literature review summarized previous findings [26] but did not conduct a meta-analysis of the results of RCTs drawing direct comparison to controls such as conventional treatment. A network meta-analysis that examined the most effective CBT format for the treatment of acute depression also did not compare for VCBT [27]. Several systematic reviews to assess the effectiveness of videoconference-delivered psychotherapy for the treatment of depression [28] and anxiety disorders [29] suggest that VCBT is an acceptable form of remote therapy for such patients, and clinical symptoms can be expected to improve. However, these reviews did not perform a meta-analysis owing to a lack of RCTs. Therefore, the estimate effect size of VCBT could not be gauged.

## **Study Objective**

As of December 2020, results from new RCTs to validate the effectiveness of VCBT for people with depressive symptoms [30-35], chronic pain, and hypochondriasis [36,37] have emerged. Therefore, there is a need for a systematic review and meta-analysis focusing on VCBT. The objective of this study is to examine the effectiveness of VCBT as a treatment option for psychiatric and somatic disorders in comparison to control conditions. The population of this review targeted both clinical and community samples. To increase the credibility of the results by reviewing high-evidence studies [38], this review included only RCTs. This study's protocol was registered with PROSERO (CRD42021224832) [39]. The protocol planned to include RCTs targeting children and adolescents. However, owing to a small number of RCTs with children and adolescents as participants [40,41], the selection criteria for this review focused on studies with adult participants. This review was in accordance with the



Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement [42], see the PRISMA checklist provided in Multimedia Appendix 1.

## Methods

## **Eligibility Criteria**

The eligibility criteria for the original studies to be a part of review were as follows: (1) subjects of the study were adults (age>18 years); (2) the intervention was VCBT; (3) the intervention group was compared to attention training (AT), treatment as usual (TAU), wait-list control (WLC), or other active control (AC) conditions; (4) the outcome was the effect of VCBT on the management of the symptoms of psychiatric or somatic disorders (primary outcome measures); (5) used a randomized control study design; and (6) were written in English. Exclusion criteria were studies in which the intervention was not based on cognitive-behavioral techniques, participants were children or adolescents, and the necessary data were inaccessible.

## **Information Sources and Search Strategy**

To identify previous studies that met our study objective, systematic searches were conducted on MEDLINE (via PubMed), Web of Science, Science Direct, PsycINFO, CINAHL, LILACS, and SciELO using the following terms related to psychiatric and somatic disorders: "depression," "panic disorder," "social phobia," "social anxiety disorder," "generalized anxiety disorder," "obsessive-compulsive disorder," "post-traumatic stress disorder," "specific phobia," "hypochondriasis," "bulimia," "tinnitus," "erectile dysfunction," "chronic pain," or "fatigue." To determine the intervention approach, these search terms were combined "videoconference," "video conference," "videoconferencing," "tele." "teleconference," "tele conference," "teleconferencing," and the search filter "randomized controlled trial" was used. The search did not include unpublished studies. Searches were last updated on December 25, 2020. Other databases were also checked (ClinicalTrials.gov and Cochrane Central Resister of Controlled Trials), along with the references of the previous systematic reviews [28,29]. For more information on the full search strategies, see the complete search strategy provided in Multimedia Appendix 2.

#### **Process of Selection and Data Collection**

A total of 2 reviewers (KM and SH) independently made decisions on whether they met the selection criteria in accordance with the aforementioned search strategy. If the selected studies did not match, the decision was made by a joint discussion among the research team, including a third party (ES). The selected studies were managed using EndNote.

# **Data Items**

Participants were those who received VCBT without restrictions, including clinical samples, community members, and students. We set the clinical symptoms as outcomes before and after the intervention. For example, if satisfaction or acceptance of the intervention was the primary outcome, a secondary outcome to measure the severity of the target disorder was adopted. The

intervention was conditional on the inclusion of having sessions with the therapist via a videoconferencing system and cognitive behavioral techniques such as behavioral activation, cognitive restructuring, exposure, and mindfulness, among others.

## **Study Risk of Bias Assessment**

The first and second authors (KM and SH) read the abstracts independently. In case of any disagreement regarding the inclusion of a particular study, the article was discussed among all researchers. All studies included in the review were assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2) [43,44]. The included studies were rated on each of the aforementioned dimensions as low risk, some concern, or high risk.

## **Statistical Analysis**

## Effect Measures

The standardized mean difference (SMD) was used in major meta-analyses because the studies included in this review used different symptom evaluation scales for the primary outcomes. The value of SMD depends on the effect size (difference in mean) and SD of the outcome (unique variation between participants). In the event of a missing summary statistic, we contacted the authors. If there was no reply, it was excluded from this review because there were no data that can be handled.

## Synthesis Methods

Statistical analysis was performed by using Cochrane Review Manager (RevMan; version 5.4.0) [43]. First, standardization was achieved by dividing the mean difference (the change from baseline to the end of the study or the value at the end of the study) by the SD of the control group in the study. Next, in a meta-analysis, the standardized mean values from individual studies were integrated to calculate the SMD. The data reflecting intention-to-treat took precedence over the per-protocol data in the meta-analysis. Intervention effects were assessed with random-effect meta-analyses, assuming variation in true effects and accounting for the hypothesized effect distribution [45,46]. A P value of  $\leq$ .05 was considered the threshold for statistical significance. According to the power calculation by Borenstein et al [45], a power of 80% to detect a small effect size required that each group has an average of 25 participants and studies be 14 or more in number (if the probability of rejecting the null hypothesis is 5%). Subgroup analyses to the estimation of intervention effects were conducted for each disorder.

The heterogeneity test and the chi-square test were performed. Significant heterogeneity of >40% suggests the presence of heterogeneity [47]. The presence and quantity of statistical heterogeneity was assessed using the P statistic, with significance set at P<.10 [48].

Sensitivity analysis was performed to compare studies that were judged to have a low risk of bias and to determine the quality of the affected outcomes.

## **Reporting Bias**

The funnel plots were visually inspected to assess the risk of bias.




## Results

#### Studies Included in the Review

Of the 3684 screened studies, 16 (N=1745) met all selection criteria and were included in the analysis. Figure 1 shows the inclusion process based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 flow diagram [49]. There was a 3-arm RCT [33]; 2 arms of those intervention groups were behavioral

activation and problem-solving. In terms of participants' conditions, 10 studies targeted depressive symptoms [30,32-35,50-54], 3 focused on chronic pain [31,37,55], 1 on obsessive-compulsive disorder [21], 1 on general anxiety disorder [56], and 1 on hypochondriasis [36]. The total number of participants from whom posttreatment data were collected was 768 in VCBT and 718 in the control conditions. Studies that reported 2 RCTs were excluded because no data were available [57,58].

Figure 1. The inclusion process. VCBT: Videoconference-Delivered Cognitive Behavioral Therapy.



#### **Characteristics of the Selected Studies**

The RCTs included in this review were conducted by 13 independent research teams. Of them, 11 were performed in the United States, 2 in the United Kingdom, 2 in Canada, and 1 in Norway. The smallest study had 27 participants and the largest

had 343 participants. All studies were published between 2008 and 2020. One RCT was configured with 2 VCBT intervention arms [33], the sample size of the control group set to half when the effect size was estimated in the meta-analysis. Table 1 presents the characteristics of each included study (see Multimedia Appendix 2 for details).



Table 1. Characteristics of the selected studies.

Selected studies	Diseases	Intervention		Participants, n		Outcomes	VCBT <sup>a</sup> , mean (SD)		Control, mean (SD)		Quality	Sampling
		CBT <sup>b</sup> technique	Control	KBL	Control		Pre	Post	Pre	Post		
Ahmad (2020) [30]	Depression	Mindfulness	WLC <sup>c</sup>	40	40	PHQ-9 <sup>d</sup>	8.1 (6.0)	6.0 (3.9)	9.1 (6.2)	9.7 (6.9)	Low risk	Community
Alschuler (2021) [31]	Pain	CBT	TAU <sup>e</sup>	15	12	PCS <sup>f</sup>	20.1 (7.8)	15.6 (10.0)	17.4 (10.2)	17.3 (9.3)	Some concerns	Clinical
Bogosian (2015) [50]	Depression	Mindfulness	WLC	19	21	Depression HADS <sup>g</sup>	6.2 (3.5)	5.1 (3.2)	7.2 (3.4)	7.6 (4.0)	Low risk	Clinical
Choi (2014) [51]	Depression	PS <sup>h</sup>	Telephone support call	43	36	HAMD <sup>i</sup>	24.6 (6.6)	13.9 (7.7)	24.6 (6.6)	19.2 (7.8)	Some concerns	Community
Choi (2020a) [32]	Depression	Behavioral activation	Tele friend- ly visits	43	46	PHQ-9	7.2 (4.0)	5.9 (3.8)	7.7 (4.5)	8.3 (4.9)	Some concerns	Community
Choi (2020b) [33]	Depression	Behavioral activation	$AC^{j}$	99	49	HAMD	23.2 (5.7)	14.6 (9.5)	22.9 (5.7)	18.1 (10.7)	Low risk	Community
Choi (2020b) [33]	Depression	PS	AC	98	49	HAMD	22.7 (5.7)	12.4 (10.6)	22.9 (5.7)	18.1 (10.7)	Low risk	Community
Demiris (2019) [56]	GAD	PS	AC	171	172	GAD-7 <sup>k</sup>	6.8 (5.3)	6.2 (4.6)	7.6 (5.2)	6.6 (4.9)	High risk	Community
Elliott (2008) [53]	Depression	PS	Education only	21	14	IDD <sup>l</sup>	11.4 (9.4)	6.1 (6.6)	4.8 (6.1)	8.8 (13.5)	Some concerns	Community
Ferguson (2016) [54]	Depression	CBT	Supportive therapy	27	20	DASS <sup>m</sup> depression	6.0 (6.6)	3.7 (4.3)	12.6 (9.4)	7.3 (7.7)	Some concerns	Clinical
EI- Jawahri (2020) [52]	Depression	CBT	TAU	45	47	HADSD	4.9 (2.8)	2.9 (5.6)	3.5 (3.4)	4.4 (5.5)	Some concerns	Clinical
Fox (2020) [34]	Depression	CBSM <sup>n</sup>	AC	95	97	PROMIS <sup>o</sup> depression	49.0 (7.3)	46.6 (9.2)	48.5 (7.4)	46.6 (8.1)	Some concerns	Clinical
EI-Morr (2020) [35]	Depression	Mindfulness	WLC	80	80	PHQ-9	8.4 (5.6)	7.0 (5.0)	9.9 (6.2)	11.2 (6.7)	Low risk	Community
Morriss (2019) [36]	Hypochondri- asis	CBT	TAU	78	78	SHAI <sup>p</sup>	24.9 (4.2)	17.7 (8.0)	25.1 (4.5)	22.6 (6.8)	Some concerns	Clinical
Somers (2018) [55]	Pain	PCST <sup>q</sup>	TAU	18	18	Pain severity	3.0 (2.1)	3.3 (2.4)	2.7 (1.9)	2.5 (1.9)	Some concerns	Clinical
Vogel (2014) [21]	OCD <sup>r</sup>	ERP <sup>s</sup>	WLC	10	10	Y-BOCS <sup>t</sup>	24.2 (4.3)	11.5 (4.8)	23.4 (2.8)	23.4 (4.8)	High risk	Clinical
Vranceanu (2019) [37]	Pain	TOR <sup>u</sup>	TAU	25	29	Physical function in SMFA <sup>W</sup>	69.8 (18.2)	20.7 (17.4)	63.2 (17.4)	48.6 (21.8)	Some concerns	Clinical



<sup>a</sup>VCBT: Videoconference-Delivered Cognitive Behavioral Therapy

<sup>b</sup>CBT: Cognitive Behavioral Therapy

<sup>c</sup>WLC: Wait-List Control

<sup>d</sup>PHQ-9: Patient Health Questionnaire, 9-item

<sup>e</sup>TAU: Treatment As Usual <sup>f</sup>PCS: Pain Catastrophizing Scale

<sup>g</sup>HADS: Hospital Anxiety and Depression Scale

<sup>h</sup>PS: Problem Solving

<sup>i</sup>HAMD: Hamilton Depression Rating Scale

<sup>j</sup>AC: Attention Control

<sup>k</sup>GAD-7: Generalized Anxiety Disorder, 7-item

<sup>1</sup>IDD: Inventory to Diagnose Depression

<sup>m</sup>DASS: Depression Anxiety Stress Scales

<sup>n</sup>CBSM: Cognitive-Behavioral Stress Management

<sup>o</sup>PROMIS: Patient-Reported Outcome Measurement Information System

<sup>p</sup>SHAI: Short Health Anxiety Inventory

<sup>q</sup>PSCBT: Problem-Solving Cognitive Behavioral Therapy

<sup>r</sup>OCD: Obsessive-Compulsive Disorder <sup>s</sup>ERP: Exposure Response Prevention

<sup>t</sup>Y-BOCS: Yale-Brown Obsessive-Compulsive Scale

<sup>u</sup>TOR: Toolkit for Optimal Recovery

WSMFA: Short Musculoskeletal Function Assessment Questionnaire

#### Risk of Bias in Studies

Evaluation of the quality of the studies included in this review shows that 4 RCTs (5 comparisons) are at a lower risk of bias [30,33,35,50], 10 RCTs are of some concern [31,32,34,36,37,51-55], and 2 RCTs are at a high risk of bias (see Multimedia Appendix 2 for details) [21,56].

# **Results of Syntheses**

Figure 2, a forest plot, shows the effect size (Hedge g) of each study and the overall effect size integrated by the meta-analysis. An effect size estimated below 0 favors guided VCBT. In all 16 studies (17 intervention arms), the pooled between-group effect size (Hedge g) was -0.49 (95% CI -0.68 to -0.29, P<.001), showing that VCBT was significantly more effective than the control conditions.

Figure 2. Forest plot. VCBT: videoconference-delivered cognitive behavioral therapy.

Name	-						-					
Included studies   Mean   SD   Total   Mean   SD   Total   Weight			VCDT		Control						-	
Ahamd et al (2020) 6.00 3.90 37 9.70 6.90 38 4.3% -0.27 [-0.97 to 0.43]  Alschuler et al (2020) 15.56 9.99 15 17.25 9.27 12 4.4% -0.60 [-1.29 to 0.08]  Bogosian et al (2020) 5.12 3.20 17 7.63 3.96 19 7.3% -0.01 [-0.38 to 0.36]  Chi et al (2020a) 5.90 3.80 43 8.30 4.90 46 7.0% -0.65 [-1.05 to -0.25]  Chi et al (2020b) 14.60 9.48 85 18.10 10.70 44 4.4% 0.36 [-0.33 to 1.04]  Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  Elliontt et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-1.17 to -0.18]  Morrise et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.08 [-0.31 to 0.14]  Vanceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  etet for overall effect Z = 4.95 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Included studies	Mean		Total			Total	Weight	iv, Kanu	om, 93% Ci		
Bogosian et al (2020) 5.12 3.20 17 7.63 3.96 19 7.3% -0.01 [-0.38 to 0.36]  Chi et al (2014) 13.90 7.70 36 19.20 7.80 31 7.7% -0.69 [-1.02 to -0.36]  Chi et al (2020a) 5.90 3.80 43 8.30 4.90 46 7.0% -0.65 [-1.05 to -0.25]  Chi et al (2020b) 14.60 9.48 85 18.10 10.70 44 4.4% 0.36 [-0.33 to 1.04]  Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -0.65 [-1.12 to -0.19]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Morr et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  Total (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); i² = 66%  Test for overall effect Z = 4.95 (P < .001)	Ahamd et al (2020)	6.00	3.90	37	9.70	6.90	38		-0.27	[-0.97 to 0.43]	I	
Chi et al (2014) 13.90 7.70 36 19.20 7.80 31 7.7% -0.69 [-1.02 to -0.36]  Chi et al (2020a) 5.90 3.80 43 8.30 4.90 46 7.0% -0.65 [-1.05 to -0.25]  Chi et al (2020b) 14.60 9.48 85 18.10 10.70 44 4.4% 0.36 [-0.33 to 1.04]  Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morr iss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  eterogeneity: Tau² = 0.10; Chì² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Alschuler et al (2020)	15.56	9.99	15	17.25	9.27	12	4.4%	-0.60	[-1.29 to 0.08]		
Chi et al (2020a) 5.90 3.80 43 8.30 4.90 46 7.0% -0.65 [-1.05 to -0.25]  Chi et al (2020b) 14.60 9.48 85 18.10 10.70 44 4.4% 0.36 [-0.33 to 1.04]  Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2010) 3.70 4.27 22 7.77 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  eterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  et for overall effect Z = 4.95 (P < .001)	Bogosian et al (2020)	5.12	3.20	17	7.63	3.96	19	7.3%	-0.01	[-0.38 to 0.36]		
Chi et al (2020b) 14.60 9.48 85 18.10 10.70 44 4.4% 0.36 [-0.33 to 1.04]  Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2020) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  leterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); l² = 66%  est for overall effect Z = 4.95 (P < .001)	Chi et al (2014)	13.90	7.70	36	19.20	7.80	31	7.7%	-0.69	[-1.02 to -0.36]		
Choi et al (2020b) 12.40 10.6 88 18.10 10.70 44 2.1% -2.37 [-3.58 to -1.17]  Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  leterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); l² = 66%  est for overall effect Z = 4.95 (P < .001)	Chi et al (2020a)	5.90	3.80	43	8.30	4.90	46	7.0%	-0.65	[-1.05 to -0.25]		
Demiris et al (2020) 6.20 4.60 141 6.60 4.90 166 5.0% -1.39 [-2.00 to -0.78]  El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.15 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  etetrogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); i² = 66%  est for overall effect Z = 4.95 (P < .001)	Chi et al (2020b)	14.60	9.48	85	18.10	10.70	44	4.4%	0.36	[-0.33 to 1.04]	-	
El-Jawahri et al (2019) 2.85 5.60 42 4.40 5.48 45 6.3% -0.65 [-1.12 to -0.19]  Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Forx et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  ieterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Choi et al (2020b)	12.40	10.6	88	18.10	10.70	44	2.1%	-2.37	[-3.58 to -1.17]		
Elliontt et al (2008) 6.05 6.62 20 8.77 13.47 13 3.9% -0.17 [-0.93 to 0.59]  Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morret al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  Reterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Demiris et al (2020)	6.20	4.60	141	6.60	4.90	166	5.0%	-1.39	[-2.00 to -0.78]	+	
Ferguson et al (2016) 3.70 4.27 22 7.27 7.66 14 4.5% -0.68 [-1.35 to -0.00]  Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% C1) 768 718 100% -0.49 [-0.68 to -0.29]  Reterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); i² = 66%  est for overall effect Z = 4.95 (P < .001)	El-Jawahri et al (2019)	2.85	5.60	42	4.40	5.48	45	6.3%	-0.65	[-1.12 to -0.19]		
Fox et al (2020) 46.55 9.16 50 46.64 8.07 64 6.0% -0.68 [-1.17 to -0.18]  Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  etetrogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Elliontt et al (2008)	6.05	6.62	20	8.77	13.47	13	3.9%	-0.17	[-0.93 to 0.59]		
Morr et al (2020) 7.04 5.03 68 11.21 6.72 80 6.8% -0.54 [-0.96 to -0.12]  Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  otal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  leterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); l² = 66%  est for overall effect Z = 4.95 (P < .001)	Ferguson et al (2016)	3.70	4.27	22	7.27	7.66	14	4.5%	-0.68	[-1.35 to -0.00]		
Morriss et al (2020) 17.70 8.00 53 22.60 6.80 48 7.4% -0.35 [-0.72 to 0.02]  Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  votal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  eterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Fox et al (2020)	46.55	9.16	50	46.64	8.07	64	6.0%	-0.68	[-1.17 to -0.18]		
Somer et al (2018) 3.28 2.40 16 2.50 1.87 17 7.3% -0.53 [-0.90 to -0.17]  Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% -0.08 [-0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% -0.28 [-0.70 to 0.15]  Votal (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  Vesterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Vesteroreall effect Z = 4.95 (P < .001)	Morr et al (2020)	7.04	5.03	68	11.21	6.72	80	6.8%	-0.54	[-0.96 to -0.12]	-	
Vogel et al (2014) 11.50 4.80 10 23.40 4.80 10 8.8% −0.08 [−0.31 to 0.14]  Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% −0.28 [−0.70 to 0.15]  iotal (95% CI) 768 718 100% −0.49 [−0.68 to −0.29]  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  est for overall effect Z = 4.95 (P < .001)	Morriss et al (2020)	17.70	8.00	53	22.60	6.80	48	7.4%	-0.35	[-0.72 to 0.02]		
Vranceanu et al (2019) 20.70 17.40 25 48.60 21.8 27 6.8% −0.28 [−0.70 to 0.15]  Fotal (95% CI) 768 718 100% −0.49 [−0.68 to −0.29]  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Fest for overall effect Z = 4.95 (P < .001)	Somer et al (2018)	3.28	2.40	16	2.50	1.87	17	7.3%	-0.53	[-0.90 to -0.17]	+-	_
total (95% CI) 768 718 100% -0.49 [-0.68 to -0.29]  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Heterogeneity: Tau² = 66%  Heterogeneity: T	Vogel et al (2014)	11.50	4.80	10	23.40	4.80	10	8.8%	-0.08	[-0.31 to 0.14]		
Heterogeneity: Tau² = 0.10; Chi² = 46.44, df=16 (P < .001); I² = 66%  Test for overall effect Z = 4.95 (P < .001)  -4 -2 0 2	Vranceanu et al (2019)	20.70	17.40	25	48.60	21.8	27	6.8%	-0.28	[-0.70 to o.15]		
Fest for overall effect Z = 4.95 (P < .001)	otal (95% CI)			768			718	100%	-0.49	[-0.68 to -0.29]		
-4 -2 0 2	leterogeneity: Tau <sup>2</sup> = 0.1	.0; Chi <sup>2</sup> = 4	46.44, df	=16 (P < .	001); l <sup>2</sup> =	66%					<b>•</b>	
VCBT Control	est for overall effect Z =	4.95 (P < .	.001)								-4 -2 0	2
											VCBT Co	ontrol

In the 10 studies (11 comparing) focused on depressive symptoms, the effect size (Hedge g) was medium, at -0.46 (95% CI -0.60 to -0.32, P<.001). In 3 studies targeting chronic pain, the effect size (Hedge g) was -0.41 (95% CI -1.49 to 0.67, P=.46), showing the effectiveness of VCBT, but was not significant. In the study targeting generalized anxiety disorder,


the effect size (Hedge g) was -0.08 (95% CI -0.31 to 0.14, P=.46). In the study targeting obsessive-compulsive disorder, the effect size (Hedge g) was -2.37 (95% CI -3.58 to -1.17, P<.001). In the study targeting hypochondriasis, the effect size (Hedge g) was -0.65 (95% CI -1.05 to -0.25, P=.001).



## **Results of the Heterogeneity Test**

Tests of heterogeneity demonstrated significant differences in effects across treatments ( $\tau^2$ =0.10;  $\chi^2_{16}$ =46.40;  $I^2$ =66%;  $I^2$ =66%;  $I^2$ =0.01). The heterogeneity was largely driven by a study conducted on exposure response prevention for obsessive-compulsive disorder [21], and 2 studies that conducted unique interventions [37,55]. If those studies were excluded, the  $I^2$  decreased from 66% to 27%: heterogeneity was not significant ( $\tau^2$ =0.02;  $\chi^2_{13}$ =17.87;  $I^2$ =16). The pooled effect size across all studies changed marginally from Hedge  $I^2$ =0.47 (95% CI –0.69 to –0.23) to Hedge  $I^2$ =0.44 (95% CI –0.59 to –0.29), if those studies were excluded from the analysis. In the 10 studies (11 comparing) on depressive symptoms, tests of heterogeneity demonstrated no differences in effects across treatments ( $I^2$ =0.01;  $I^2$ =11.09;  $I^2$ =10%;  $I^2$ =35).

Figure 3. Funnel plot. SMD: standardized mean difference.



# Discussion

## **Principal Findings**

The objective of this systematic review was to investigate the effectiveness of VCBT as an intervention strategy as compared to control conditions such as AC, AT, TAU, and WLC using meta-analysis. Taken together, the results of this meta-analysis suggest that the pooled effect size of the primary outcomes of each disorder is medium, indicating that VCBT is especially effective for depressive symptoms. The novelty of this meta-analytic review lies in integrating the effectiveness of VCBT for psychiatric and somatic disorders, extending current knowledge into the field of remote psychotherapy [28,29,59]. However, most of the RCTs included in this review targeted depression. Therefore, further RCTs should be performed to accurately estimate the effectiveness of VCBT for generalized anxiety disorder, obsessive-compulsive disorder, chronic pain, and hypochondriasis. The quality of the study in the 16 RCTs (17 comparisons) was evaluated using RoB [43]: only 4 studies (5 comparisons) showed a low risk of bias, 10 showed some concern, and 2 showed a high risk of bias. Meta-analysis with the 4 studies (low risk of bias) revealed a moderate effect size and no heterogeneity for the effectiveness of VCBT. This result was also similar to those of a meta-analysis of 11 studies in which other judgments were made for all 16 RCTs (17 comparisons) and other bias risks. Therefore, the findings of

## **Results of Sensitivity Analysis**

Subgroup analysis was conducted to verify an association between the studies' quality and intervention effects. In the 4 studies (5 comparisons) judged to have a low risk of bias, the estimated pooled effect size (Hedge g) was -0.56 (95% CI -0.74 to -0.38, P<.001;  $\tau^2<0.001$ ,  $\chi^2_4=2.13$ , P=.71;  $I^2=0\%$ ) and -0.42 (95% CI -0.69 to -0.16, P=.002;  $\tau^2=0.15$ ,  $\chi^2_{12}=42.01$ , P<.001;  $I^2=71\%$ ) for the other 11 studies. Thus, our results suggest that study quality did not significantly affect intervention effects.

#### **Publication Bias**

Figure 3 displays a funnel plot. Effect sizes were not evenly distributed around the averaged effect. The lower-right section of the funnel plot is devoid of studies, which suggests that there was bias in the pooled effect estimate owing to unpublished studies.

this systematic and meta-analysis suggest evidence that VCBT is also effective for diseases for which face-to-face and guided ICBT have been demonstrated [8,16,17].

## Strengths of the Review

This meta-analysis has several strengths. The results of this systematic review and meta-analysis for psychiatric disorders extend support in favor of VCBT as an effective mode of intervention. Prior systematic reviews of CBT utilizing videoconferencing systems did not include meta-analysis [28,29]. Furthermore, this study has integrated the results of RCTs that directly compared the effectiveness of VCBT for typical psychiatric disorders with minimal intervention. Our results provide useful information for clinicians and policy makers to take the practicality of VCBT into account, especially in response to the COVID-19 pandemic [60].

#### Limitations

This study also has some limitations. First, the analyzed studies were highly heterogeneous. Second, this study adopted a broad definition of CBT. CBT is a broad concept that includes treatment methods such as cognitive therapy, behavioral therapy, acceptance and commitment therapy, behavioral activation, problem-solving techniques, and prolonged exposure therapy. Therefore, the effect size should ideally be estimated for each therapeutic technique in the future, as was performed in a previous review of cognitive therapy for depression [61].



However, the effectiveness of each cognitive behavioral technique could not be calculated in this study, owing to the small number of pre-existing studies to analyze intervention categories and subcategories. Furthermore, owing to the inconsistent control criteria in this review, it is not possible to assess the exact effectiveness of VCBT. The gold-standard design for estimating the effect of treatment is RCT with psychological or the pill placebo group [62]. These control conditions can be standardized to control the impact of patient expectations on outcomes. Therefore, to estimate the effectiveness of VCBT accurately, it is necessary to perform a meta-analysis at the stage when RCT with psychological or pill placebo group is sufficiently accumulated. Further, this review only included studies that used adult participants owing to the low number of RCTs for children and adolescents. In future, RCTs to evaluate the effectiveness of VCBT should also be conducted on samples of children and adolescents. Since we only included articles written in English, we need to examine studies reported in more diverse languages in the future. Finally, long-term effectiveness of VCBT was not analyzed. Since this study succeeded in demonstrating the short-term effectiveness of VCBT for adult psychiatric disorders and somatic symptom disorders, the results of long-term effectiveness in the future RCTs should also be integrated.

#### **Comparison With Prior Work**

Our results, indicating that VCBT is effective for somatic disorders, extend support to those of Liu et al [9], who compared VCBT and face-to-face CBT. Additionally, the overall effect size estimated in this meta-analysis is very similar to previous results on face-to-face CBT and computerized CBT for treatment of depression and anxiety, compared to primary care TAU [61,63]. Furthermore, the effect size (Hedge g=0.46, medium effect size) of VCBT for depressive symptoms is consistent with previous results (Hedge g=0.71, large effect size) of a bias-adjusted meta-analysis [64]. Therefore, our findings demonstrate the effectiveness of VCBT as a treatment option for adults with psychiatric disorders.

This review did not include exposure techniques except for an RCT by Vogle et al [21]. Real-time interventions that utilize videoconferencing systems have the advantage of exposing the home environment of the patient [65]. At the same time, it is difficult to match up to the interpersonal experience of working

with a therapist to resolve the issues, especially in the treatment for disorders that require exposure therapy such as obsessive-compulsive disorder and panic disorder. In case of obsessive-compulsive disorder, patients are afraid of things such as hospital floors, rags, and toilet paper. In case of panic disorder, the task of working with the therapist to climb stairs and exercise may be difficult to perform. Therefore, it would be premature to determine the effectiveness of VCBT for patients with anxiety disorders from the effect sizes shown in this review. The results of clinical studies that were not RCTs show that VCBT is sufficient to improve symptoms of obsessive-compulsive disorder and panic disorder [18,21,65], where exposure is an important therapeutic component [66,67]. In the future, tightly controlled RCTs are expected to be implemented, and this review should be updated with regard to the calculation of integrated estimated effect sizes for those disorders.

The number of studies included in the analysis corresponding to each condition was small, except for depressive symptoms. However, the total number of studies and participants made it possible to detect significant differences between VCBT and control conditions. However, the high degree of heterogeneity indicates the need for careful interpretation of our results. While the risk of bias detected in the quality assessment appeared to have an overall minor impact, there may be publication bias, as no negative results were reported. Namely, the funnel plot in this study suggests that there was bias in the pooled effect estimate owing to unpublished studies. Positive findings are thrice more likely to be published than negative findings [68]; hence, careful interpretation of our results is required.

## **Conclusions**

This study attempted to provide evidence in favor of the effectiveness of VCBT as a feasible alternative approach to service patients with poor access to face-to-face CBT. VCBT, has the advantage of facilitating real-time communication between patients and therapists. This has important implications for clinicians and policy makers because it is a well-accepted approach that has demonstrated a high degree of satisfaction [19]. Although more studies are needed to draw firm conclusions, findings such as those from our meta-analysis show that VCBT is a promising treatment for future use [69].

## Acknowledgments

This study was supported by the Japan Society for the Promotion of Science KAKENHI Grant-in-aide for Scientific Research, Grant Number 18K03130 and 18K17313. We would like to thank Editage (www.editage.com) for English language editing.

## **Conflicts of Interest**

None declared.

# Multimedia Appendix 1

PRISMA 2020 checklist.

[PDF File (Adobe PDF File), 58 KB-Multimedia Appendix 1]



## Multimedia Appendix 2

The complete search strategy, details of the included studies, and list of excluded studies. [PDF File (Adobe PDF File), 1752 KB-Multimedia Appendix 2]

#### References

- 1. GBD 2017 DiseaseInjury IncidencePrevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018 Nov 10;392(10159):1789-1858 [FREE Full text] [doi: 10.1016/S0140-6736(18)32279-7] [Medline: 30496104]
- 2. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008 Apr;69(4):621-632 [FREE Full text] [doi: 10.4088/jcp.v69n0415] [Medline: 18363421]
- 3. Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res 2012 Oct 01;36(5):427-440 [FREE Full text] [doi: 10.1007/s10608-012-9476-1] [Medline: 23459093]
- 4. Field T, Beeson E, Jones L. The New ABCs: A Preactitioner?s Guide to Neuroscience-Informed Cogntiive-Behavior Therapy. J Ment Health Couns 2015;37(3):A. [doi: 10.17744/1040-2861-37.3.206]
- 5. Hofmann SG, Asmundson GJG, Beck AT. The science of cognitive therapy. Behav Ther 2013 Jun;44(2):199-212. [doi: 10.1016/j.beth.2009.01.007] [Medline: 23611069]
- 6. Brewin CR. Theoretical foundations of cognitive-behavior therapy for anxiety and depression. Annu Rev Psychol 1996;47:33-57. [doi: 10.1146/annurev.psych.47.1.33] [Medline: 8624137]
- 7. Schacter D, Gilbert D, Wegner DM. Psychology (2nd edition). New York, NY: Worth; 2011.
- 8. Carpenter JK, Andrews LA, Witcraft SM, Powers MB, Smits JAJ, Hofmann SG. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety 2018 Jun;35(6):502-514 [FREE Full text] [doi: 10.1002/da.22728] [Medline: 29451967]
- 9. Liu J, Gill NS, Teodorczuk A, Li Z, Sun J. The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials. J Affect Disord 2019 Feb 15;245:98-112. [doi: 10.1016/j.jad.2018.10.114] [Medline: 30368076]
- 10. David D, Cristea I, Hofmann SG. Why Cognitive Behavioral Therapy Is the Current Gold Standard of Psychotherapy. Front Psychiatry 2018;9:4 [FREE Full text] [doi: 10.3389/fpsyt.2018.00004] [Medline: 29434552]
- 11. Whiston A, Bockting CLH, Semkovska M. Towards personalising treatment: a systematic review and meta-analysis of face-to-face efficacy moderators of cognitive-behavioral therapy and interpersonal psychotherapy for major depressive disorder. Psychol Med 2019 Dec;49(16):2657-2668. [doi: 10.1017/S0033291719002812] [Medline: 31615583]
- 12. Mental disorders. World Health Organization. 2019. URL: <a href="https://www.who.int/news-room/fact-sheets/detail/mental-disorders">https://www.who.int/news-room/fact-sheets/detail/mental-disorders</a> [accessed 2021-03-13]
- 13. Johnson J. Worldwide digital population as of October 2020. Statista, Internet, Demographics & Use 2021. URL: <a href="https://www.statista.com/statistics/617136/digital-population-worldwide/z">https://www.statista.com/statistics/617136/digital-population-worldwide/z</a> [accessed 2021-03-13]
- 14. Watts SE, Andrews G. Internet access is NOT restricted globally to high income countries: so why are evidenced based prevention and treatment programs for mental disorders so rare? Asian J Psychiatr 2014 Aug;10:71-74. [doi: 10.1016/j.ajp.2014.06.007] [Medline: 25042956]
- 15. Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults. Cochrane Database Syst Rev 2016 Mar 12;3:CD011565 [FREE Full text] [doi: 10.1002/14651858.CD011565.pub2] [Medline: 26968204]
- 16. Andersson G, Cuijpers P, Carlbring P, Riper H, Hedman E. Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry 2014 Oct;13(3):288-295 [FREE Full text] [doi: 10.1002/wps.20151] [Medline: 25273302]
- 17. Carlbring P, Andersson G, Cuijpers P, Riper H, Hedman-Lagerlöf E. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. Cogn Behav Ther 2018 Jan;47(1):1-18. [doi: 10.1080/16506073.2017.1401115] [Medline: 29215315]
- 18. Hamatani S, Numata N, Matsumoto K, Sutoh C, Ibuki H, Oshiro K, et al. Internet-Based Cognitive Behavioral Therapy via Videoconference for Patients With Bulimia Nervosa and Binge-Eating Disorder: Pilot Prospective Single-Arm Feasibility Trial. JMIR Form Res 2019 Oct 23;3(4):e15738 [FREE Full text] [doi: 10.2196/15738] [Medline: 31647472]
- 19. Matsumoto K, Sutoh C, Asano K, Seki Y, Urao Y, Yokoo M, et al. Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial. J Med Internet Res 2018 Dec 17;20(12):e12091 [FREE Full text] [doi: 10.2196/12091] [Medline: 30559094]



- Stubbings DR, Rees CS, Roberts LD, Kane RT. Comparing in-person to videoconference-based cognitive behavioral therapy for mood and anxiety disorders: randomized controlled trial. J Med Internet Res 2013 Nov 19;15(11):e258 [FREE Full text] [doi: 10.2196/jmir.2564] [Medline: 24252663]
- 21. Vogel PA, Solem S, Hagen K, Moen EM, Launes G, Håland ÅT, et al. A pilot randomized controlled trial of videoconference-assisted treatment for obsessive-compulsive disorder. Behav Res Ther 2014 Dec;63:162-168. [doi: 10.1016/j.brat.2014.10.007] [Medline: 25461792]
- 22. Acierno R, Gros DF, Ruggiero KJ, Hernandez-Tejada MA, Knapp RG, Lejuez CW, et al. Behavioral activation and therapeutic exposure for posttraumatic stress disorder: a noninferiority trial of treatment delivered in person versus home-based telehealth. Depress Anxiety 2016 May;33(5):415-423. [doi: 10.1002/da.22476] [Medline: 26864655]
- 23. Acierno R, Knapp R, Tuerk P, Gilmore AK, Lejuez C, Ruggiero K, et al. A non-inferiority trial of Prolonged Exposure for posttraumatic stress disorder: In person versus home-based telehealth. Behav Res Ther 2017 Feb;89:57-65 [FREE Full text] [doi: 10.1016/j.brat.2016.11.009] [Medline: 27894058]
- 24. Egede LE, Acierno R, Knapp RG, Lejuez C, Hernandez-Tejada M, Payne EH, et al. Psychotherapy for depression in older veterans via telemedicine: a randomised, open-label, non-inferiority trial. Lancet Psychiatry 2015 Aug;2(8):693-701. [doi: 10.1016/S2215-0366(15)00122-4] [Medline: 26249300]
- 25. Morland LA, Mackintosh M, Rosen CS, Willis E, Resick P, Chard K, et al. Telemedicine versus in-person delivery of cognitive processing therapy for women with posttraumatic stress disorder: randomized noninferiority trial. Depress Anxiety 2015 Nov;32(11):811-820. [doi: 10.1002/da.22397] [Medline: 26243685]
- 26. Thomas N, McDonald C, de Boer K, Brand RM, Nedeljkovic M, Seabrook L. Review of the current empirical literature on using videoconferencing to deliver individual psychotherapies to adults with mental health problems. Psychol Psychother 2021 Sep;94(3):854-883 [FREE Full text] [doi: 10.1111/papt.12332] [Medline: 33620133]
- Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis. JAMA Psychiatry 2019 Jul 01;76(7):700-707 [FREE Full text] [doi: 10.1001/jamapsychiatry.2019.0268] [Medline: 30994877]
- 28. Berryhill MB, Culmer N, Williams N, Halli-Tierney A, Betancourt A, Roberts H, et al. Videoconferencing Psychotherapy and Depression: A Systematic Review. Telemed J E Health 2019 Jun;25(6):435-446. [doi: 10.1089/tmj.2018.0058] [Medline: 30048211]
- 29. Rees CS, Maclaine E. A Systematic Review of Videoconference Delivered Psychological Treatment for Anxiety Disorders. Australian Psychologist 2020 Nov 12;50(4):259-264. [doi: 10.1111/ap.12122]
- 30. Ahmad F, El Morr C, Ritvo P, Othman N, Moineddin R, Team MVC. An Eight-Week, Web-Based Mindfulness Virtual Community Intervention for Students' Mental Health: Randomized Controlled Trial. JMIR Ment Health 2020 Feb 18;7(2):e15520 [FREE Full text] [doi: 10.2196/15520] [Medline: 32074061]
- 31. Alschuler KN, Altman JK, Ehde DM. Feasibility and acceptability of a single-session, videoconference-delivered group intervention for pain in multiple sclerosis. Rehabil Psychol 2021 Feb;66(1):22-30. [doi: 10.1037/rep0000360] [Medline: 32790454]
- 32. Choi NG, Pepin R, Marti CN, Stevens CJ, Bruce ML. Improving Social Connectedness for Homebound Older Adults: Randomized Controlled Trial of Tele-Delivered Behavioral Activation Versus Tele-Delivered Friendly Visits. Am J Geriatr Psychiatry 2020 Jul;28(7):698-708. [doi: 10.1016/j.jagp.2020.02.008] [Medline: 32238297]
- 33. Choi NG, Marti CN, Wilson NL, Chen GJ, Sirrianni L, Hegel MT, et al. Effect of Telehealth Treatment by Lay Counselors vs by Clinicians on Depressive Symptoms Among Older Adults Who Are Homebound: A Randomized Clinical Trial. JAMA Netw Open 2020 Aug 03;3(8):e2015648 [FREE Full text] [doi: 10.1001/jamanetworkopen.2020.15648] [Medline: 32865577]
- 34. Fox RS, Moreno PI, Yanez B, Estabrook R, Thomas J, Bouchard LC, et al. Integrating PROMIS® computerized adaptive tests into a web-based intervention for prostate cancer. Health Psychol 2019 May;38(5):403-409 [FREE Full text] [doi: 10.1037/hea0000672] [Medline: 31045423]
- 35. El Morr C, Ritvo P, Ahmad F, Moineddin R, Team MVC. Correction: Effectiveness of an 8-Week Web-Based Mindfulness Virtual Community Intervention for University Students on Symptoms of Stress, Anxiety, and Depression: Randomized Controlled Trial. JMIR Ment Health 2020 Jul 17;7(7):e18595 [FREE Full text] [doi: 10.2196/18595] [Medline: 32554380]
- 36. Morriss R, Patel S, Malins S, Guo B, Higton F, James M, et al. Clinical and economic outcomes of remotely delivered cognitive behaviour therapy versus treatment as usual for repeat unscheduled care users with severe health anxiety: a multicentre randomised controlled trial. BMC Med 2019 Jan 23;17(1):16 [FREE Full text] [doi: 10.1186/s12916-019-1253-5] [Medline: 30670044]
- 37. Vranceanu A, Jacobs C, Lin A, Greenberg J, Funes CJ, Harris MB, et al. Results of a feasibility randomized controlled trial (RCT) of the Toolkit for Optimal Recovery (TOR): a live video program to prevent chronic pain in at-risk adults with orthopedic injuries. Pilot Feasibility Stud 2019;5:30 [FREE Full text] [doi: 10.1186/s40814-019-0416-7] [Medline: 30820341]
- 38. Greenhalgh T. How to Read a Paper: The Basics of Evidence-Based Medicine. London: BMJ Books; 2014. [doi: 10.1136/bmj.315.7112.891]



- 39. Matsumoto K, Hamatani S, Shimizu E. Effectiveness of remote cognitive behavioral therapy via videoconference for psychiatric and somatic disorders: a systematic review and meta-analysis. PROSPERO 2021 CRD42021224832. 2021. URL: <a href="https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42021224832">https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42021224832</a> [accessed 2021-06-16]
- 40. Wade SL, Carey J, Wolfe CR. An online family intervention to reduce parental distress following pediatric brain injury. J Consult Clin Psychol 2006 Jun;74(3):445-454. [doi: 10.1037/0022-006X.74.3.445] [Medline: 16822102]
- 41. Wade SL, Walz NC, Carey J, McMullen KM, Cass J, Mark E, et al. A randomized trial of teen online problem solving: efficacy in improving caregiver outcomes after brain injury. Health Psychol 2012 Nov;31(6):767-776. [doi: 10.1037/a0028440] [Medline: 22746261]
- 42. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021 Mar 29;372:n71 [FREE Full text] [doi: 10.1136/bmj.n71] [Medline: 33782057]
- 43. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. London: The Cochran Collaboration; 2011.
- 44. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019 Aug 28;366:14898. [doi: 10.1136/bmj.14898] [Medline: 31462531]
- 45. Bogosian A, Chadwick P, Windgassen S, Norton S, McCrone P, Mosweu I, et al. Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Mult Scler 2015 Aug 28;21(9):1184-1194 [FREE Full text] [doi: 10.1177/1352458515576261] [Medline: 25767124]
- 46. Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood 2010 Oct 28;116(17):3140-3146 [FREE Full text] [doi: 10.1182/blood-2010-05-280883] [Medline: 20656933]
- 47. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002 Jun 15;21(11):1539-1558. [doi: 10.1002/sim.1186] [Medline: 12111919]
- 48. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 06;327(7414):557-560 [FREE Full text] [doi: 10.1136/bmj.327.7414.557] [Medline: 12958120]
- 49. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021 Mar 29;372:n71 [FREE Full text] [doi: 10.1136/bmj.n71] [Medline: 33782057]
- 50. Bogosian A, Chadwick P, Windgassen S, Norton S, McCrone P, Mosweu I, et al. Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Mult Scler 2015 Aug;21(9):1184-1194. [doi: 10.1177/1352458515576261] [Medline: 25767124]
- 51. Choi NG, Hegel MT, Marti N, Marinucci ML, Sirrianni L, Bruce ML. Telehealth problem-solving therapy for depressed low-income homebound older adults. Am J Geriatr Psychiatry 2014 Mar;22(3):263-271 [FREE Full text] [doi: 10.1097/JGP.0b013e318266b356] [Medline: 23567376]
- 52. El-Jawahri A, Jacobs JM, Nelson AM, Traeger L, Greer JA, Nicholson S, et al. Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial. Cancer 2020 Apr 15;126(8):1758-1765 [FREE Full text] [doi: 10.1002/cncr.32680] [Medline: 31899552]
- 53. Elliott TR, Brossart D, Berry JW, Fine P. Problem-solving training via videoconferencing for family caregivers of persons with spinal cord injuries: a randomized controlled trial. Behav Res Ther 2008 Nov;46(11):1220-1229. [doi: 10.1016/j.brat.2008.08.004] [Medline: 18828993]
- 54. Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, et al. A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 2016 Jun 01;122(11):1782-1791 [FREE Full text] [doi: 10.1002/cncr.29891] [Medline: 27135464]
- 55. Somers TJ, Kelleher SA, Dorfman CS, Shelby RA, Fisher HM, Rowe Nichols K, et al. An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. JMIR Mhealth Uhealth 2018 Mar 19;6(3):e66-e30 [FREE Full text] [doi: 10.2196/mhealth.8565] [Medline: 29555620]
- 56. Demiris G, Oliver DP, Washington K, Pike K. A Problem-Solving Intervention for Hospice Family Caregivers: A Randomized Clinical Trial. J Am Geriatr Soc 2019 Jul 19;67(7):1345-1352 [FREE Full text] [doi: 10.1111/jgs.15894] [Medline: 30946495]
- 57. Scogin F, Lichstein K, DiNapoli EA, Woosley J, Thomas SJ, LaRocca MA, et al. Effects of Integrated Telehealth-Delivered Cognitive-Behavioral Therapy for Depression and Insomnia in Rural Older Adults. J Psychother Integr 2018 Sep;28(3):292-309 [FREE Full text] [doi: 10.1037/int0000121] [Medline: 30930607]
- 58. Milbury K, Li Y, Durrani S, Liao Z, Tsao AS, Carmack C, et al. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist 2020 Nov;25(11):e1794-e1802 [FREE Full text] [doi: 10.1634/theoncologist.2020-0125] [Medline: 32621630]
- 59. Probst T, Haid B, Schimböck W, Reisinger A, Gasser M, Eichberger-Heckmann H, et al. Therapeutic interventions in in-person and remote psychotherapy: Survey with psychotherapists and patients experiencing in-person and remote psychotherapy during COVID-19. Clin Psychol Psychother 2021 Jul;28(4):988-1000 [FREE Full text] [doi: 10.1002/cpp.2553] [Medline: 33448499]



- 60. World Health Organization. WHO Directory-Generial's opening remarks at the media briefing on COVID-19 11 March 2020. World Health Organization.: World Health Organization; 2020 Mar 11. URL: <a href="https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020">https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</a> [accessed 2021-11-29]
- 61. Twomey C, O'Reilly G, Byrne M. Effectiveness of cognitive behavioural therapy for anxiety and depression in primary care: a meta-analysis. Fam Pract 2015 Mar;32(1):3-15 [FREE Full text] [doi: 10.1093/fampra/cmu060] [Medline: 25248976]
- 62. Lavori P. Placebo control groups in randomized treatment trials: a statistician's perspective. Biological Psychiatry 2000 Apr;47(8):717-723. [doi: 10.1016/s0006-3223(00)00838-6] [Medline: 25248976]
- 63. Santoft F, Axelsson E, Öst LG, Hedman-Lagerlöf M, Fust J, Hedman-Lagerlöf E. Cognitive behaviour therapy for depression in primary care: systematic review and meta-analysis. Psychol Med 2019 Jun 15;49(8):1266-1274. [doi: 10.1017/S0033291718004208] [Medline: 30688184]
- 64. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013 Jul;58(7):376-385. [doi: 10.1177/070674371305800702] [Medline: 23870719]
- 65. Kishimoto T, Tarumi S, Mimura M. Exposure response prevention utilizing telemedicine-case series of three cases. Japanese journal of clinical psychiatry 2016;45(12):1603-1609 [FREE Full text]
- 66. Reid JE, Laws KR, Drummond L, Vismara M, Grancini B, Mpavaenda D, et al. Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis of randomised controlled trials. Compr Psychiatry 2021 Apr;106(12):152223-151609 [FREE Full text] [doi: 10.1016/j.comppsych.2021.152223] [Medline: 33618297]
- 67. Pompoli A, Furukawa TA, Efthimiou O, Imai H, Tajika A, Salanti G. Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. Psychol Med 2018 Sep;48(12):1945-1953 [FREE Full text] [doi: 10.1017/S0033291717003919] [Medline: 29368665]
- 68. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997 Sep 13;315(7109):640-645 [FREE Full text] [doi: 10.1136/bmj.315.7109.640] [Medline: 9310565]
- 69. Zargaran D, Walsh C, Koumpa FS, Ashraf MA, White AJ, Patel N, et al. Comment on "Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial". J Med Internet Res 2020 Aug 12;22(8):e13234-e13645 [FREE Full text] [doi: 10.2196/13234] [Medline: 32784172]

# Abbreviations

**AC:** active control **AT:** attention training

CBT: cognitive behavioral therapy

**ICBT:** internet-based cognitive behavioral therapy

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

**RCT:** randomized controlled trial **SMD:** standardized mean difference

TAU: treatment as usual

VCBT: videoconference-delivered cognitive behavioral therapy

WLC: wait-list control

Edited by R Kukafka; submitted 22.06.21; peer-reviewed by K Matthias; comments to author 21.07.21; revised version received 14.09.21; accepted 29.10.21; published 13.12.21

Please cite as:

Matsumoto K, Hamatani S, Shimizu E

Effectiveness of Videoconference-Delivered Cognitive Behavioral Therapy for Adults With Psychiatric Disorders: Systematic and Meta-Analytic Review

J Med Internet Res 2021;23(12):e31293 URL: https://www.jmir.org/2021/12/e31293

doi: 10.2196/31293

PMID:

©Kazuki Matsumoto, Sayo Hamatani, Eiji Shimizu. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 13.12.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution



## JOURNAL OF MEDICAL INTERNET RESEARCH

Matsumoto et al

License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.

